Share
News

FDA Announces Hydroxycloroquine Decision

Share

U.S. regulators on Monday revoked emergency authorization for antimalarial drugs promoted by President Donald Trump for treating COVID-19.

The Food and Drug Administration said the drugs hydroxychloroquine and chloroquine are unlikely to be effective in treating the coronavirus.

Citing reports of heart complications, the FDA said in a news release that the drugs’ unproven benefits “do not outweigh the known and potential risks.”

“While additional clinical trials continue to evaluate the potential benefit of these drugs in treating or preventing COVID-19, we determined the emergency use authorization was no longer appropriate,” Dr. Patrizia Cavazzoni, acting director of the FDA’s Center for Drug Evaluation, said in a statement. “This action was taken following a rigorous assessment by scientists in our Center for Drug Evaluation and Research.

“We remain committed to using every tool at our disposal in collaboration with innovators and researchers to provide sick patients timely access to appropriate new therapies. Our decisions will always be based on objective and rigorous evaluation of the scientific data. This will never change.”

Trending:
One Crucial Official Was Nowhere to Be Seen as Biden Attends Tribute for 491 Fallen Officers

The decades-old drugs, also prescribed for lupus and rheumatoid arthritis, can cause heart rhythm problems, severely low blood pressure and muscle or nerve damage.

The move means that shipments of the drugs obtained by the federal government will no longer be distributed to state and local health authorities for use against the coronavirus.

The drugs are still available for alternate uses, so U.S. doctors could still prescribe them for COVID-19.

“Of note, FDA approved products may be prescribed by physicians for off-label uses if they determine it is appropriate for treating their patients, including during COVID,” the FDA news release said.

Do you agree with the FDA's decision?

Many Americans have shared stories of hydroxychloroquine’s effectiveness against the coronavirus.

Democratic Michigan state Rep. Karen Whitsett is among them.

“For me, it saved my life,” Whitsett said in April. “I only can go by what it is that I have gone through and what my story is, and I can’t speak for anyone else.”

Carlos Gavidia had a similar experience. The Jupiter, Florida, resident credited hydroxychloroquine, along with the antibiotic azithromycin, with his recovery from COVID-19, and he thanked the president for touting the treatment.

Others, however, have dismissed such anecdotal evidence.

Related:
Gear Up to Vaccinate Your Children; Health Officials Are Pushing States to Order What's Required

Dr. Steven Nissen, a Cleveland Clinic researcher who has been a frequent FDA adviser, agreed with the agency’s decision and said he would not have granted emergency access in the first place.

“There has never been any high-quality evidence suggesting that hydroxychloroquine is effective” for treating or preventing coronavirus infection, he said, but there is evidence of serious side effects.

On Thursday, a National Institutes of Health panel of experts revised its recommendations to specifically recommend against the drug’s use except in formal studies, and “that, I’m sure, had influence on the FDA,” Nissen said.

Trump promoted hydroxychloroquine as a possible coronavirus treatment in the early weeks of the outbreak and revealed last month that he was taking the drug pre-emptively against infection.

No large, rigorous studies have found the antimalarial drugs safe or effective for preventing or treating COVID-19, and some recent studies indicate they could do more harm than good.

The FDA granted emergency use of the drugs for coronavirus patients in late March at the same time the U.S. government accepted 30 million doses of hydroxychloroquine and chloroquine that had been donated by two foreign drug manufacturers. Millions of those doses were shipped to U.S. hospitals to treat patients who weren’t enrolled in clinical trials.

The agency said Monday it revoked the authorization in consultation with the Biomedical Advanced Research and Development Authority, or BARDA, which had requested the emergency use.

The Western Journal has reviewed this Associated Press story and may have altered it prior to publication to ensure that it meets our editorial standards.

Truth and Accuracy

Submit a Correction →



loading

We are committed to truth and accuracy in all of our journalism. Read our editorial standards.

Tags:
, , , , , , ,
Share
The Associated Press is an independent, not-for-profit news cooperative headquartered in New York City. Their teams in over 100 countries tell the world’s stories, from breaking news to investigative reporting. They provide content and services to help engage audiences worldwide, working with companies of all types, from broadcasters to brands.
The Associated Press was the first private sector organization in the U.S. to operate on a national scale. Over the past 170 years, they have been first to inform the world of many of history's most important moments, from the assassination of Abraham Lincoln and the bombing of Pearl Harbor to the fall of the Shah of Iran and the death of Pope John Paul.

Today, they operate in 263 locations in more than 100 countries relaying breaking news, covering war and conflict and producing enterprise reports that tell the world's stories.
Location
New York City




loading

Conversation